Studies on the mechanism of the human natural killer cell lethal hit: evidence for transfer of protease-sensitive structures requisite for target cell lysis. 1983

J C Hiserodt, and L J Britvan, and S R Targan

These studies analyze the effects of various enzymes on the terminal, killer cell-independent (KCIL) stages of the human natural killer (NK) cytolytic mechanism. The addition of trypsin (T), chymotrypsin (CT), or papain (P) to standard NK reaction mixtures (PBL or LGL and K562 cells) completely ablated cytolytic activity, whereas collagenase was ineffective. Inhibition by T was reversed by preincubation with soybean trypsin inhibitor (SBTI) or fetal calf serum, indicating that the inhibition was indeed due to T. Kinetic analysis with the Ca++ pulse experiment indicated that T, CT, and P inhibited lysis well beyond the Ca++-dependent (EDTA-sensitive) stages and essentially stopped further 51Cr release at the time of addition. This observation was confirmed by the ability of T, CT, and P to block lysis during KCIL of programmed K562 targets that were detached from NK cells by EDTA and were suspended in dextran-containing media. The lysis of K562 cells by natural killer cell-derived cytotoxic factors (NKCF) was also blocked by T and CT but not by P. Inhibition of NKCF activity by T could be reversed by SBTI or fetal calf serum. The ability of T, CT, or P to inhibit the lysis of "programmed" K562 targets during KCIL indicates that the NK lethal hit is an active process mediated by protease-sensitive structures, possibly NKCF, delivered to the target cell by the NK cell during the Ca++-dependent programming steps.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008233 Lymphotoxin-alpha A tumor necrosis factor family member that is released by activated LYMPHOCYTES. Soluble lymphotoxin is specific for TUMOR NECROSIS FACTOR RECEPTOR TYPE I; TUMOR NECROSIS FACTOR RECEPTOR TYPE II; and TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14. Lymphotoxin-alpha can form a membrane-bound heterodimer with LYMPHOTOXIN-BETA that has specificity for the LYMPHOTOXIN BETA RECEPTOR. TNF Superfamily, Member 1,TNF-beta,Tumor Necrosis Factor Ligand Superfamily Member 1,Tumor Necrosis Factor-beta,Lymphotoxin,Lymphotoxin-alpha3,Soluble Lymphotoxin-alpha,alpha-Lymphotoxin,Lymphotoxin alpha,Lymphotoxin alpha3,Lymphotoxin-alpha, Soluble,Soluble Lymphotoxin alpha,Tumor Necrosis Factor beta,alpha Lymphotoxin
D010206 Papain A proteolytic enzyme obtained from Carica papaya. It is also the name used for a purified mixture of papain and CHYMOPAPAIN that is used as a topical enzymatic debriding agent. EC 3.4.22.2. Tromasin
D010447 Peptide Hydrolases Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. Peptidase,Peptidases,Peptide Hydrolase,Protease,Proteases,Proteinase,Proteinases,Proteolytic Enzyme,Proteolytic Enzymes,Esteroproteases,Enzyme, Proteolytic,Hydrolase, Peptide
D001790 Blood Physiological Phenomena Physiological processes and properties of the BLOOD. Blood Physiologic Processes,Blood Physiological Processes,Blood Physiology,Blood Physiological Concepts,Blood Physiological Phenomenon,Physiology, Blood,Blood Physiological Concept,Blood Physiological Phenomenas,Concept, Blood Physiological,Concepts, Blood Physiological,Phenomena, Blood Physiological,Phenomenon, Blood Physiological,Physiologic Processes, Blood,Physiological Concept, Blood,Physiological Concepts, Blood,Physiological Phenomenon, Blood,Processes, Blood Physiologic,Processes, Blood Physiological
D002918 Chymotrypsin A serine endopeptidase secreted by the pancreas as its zymogen, CHYMOTRYPSINOGEN and carried in the pancreatic juice to the duodenum where it is activated by TRYPSIN. It selectively cleaves aromatic amino acids on the carboxyl side. Alpha-Chymotrypsin Choay,Alphacutanée,Avazyme
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D014357 Trypsin A serine endopeptidase that is formed from TRYPSINOGEN in the pancreas. It is converted into its active form by ENTEROPEPTIDASE in the small intestine. It catalyzes hydrolysis of the carboxyl group of either arginine or lysine. EC 3.4.21.4. Tripcellim,Trypure,beta-Trypsin,beta Trypsin

Related Publications

J C Hiserodt, and L J Britvan, and S R Targan
January 1987, Annales de l'Institut Pasteur. Immunology,
J C Hiserodt, and L J Britvan, and S R Targan
July 1984, Journal of immunology (Baltimore, Md. : 1950),
J C Hiserodt, and L J Britvan, and S R Targan
January 1985, Advances in experimental medicine and biology,
J C Hiserodt, and L J Britvan, and S R Targan
January 1981, International journal of cancer,
J C Hiserodt, and L J Britvan, and S R Targan
January 1982, Advances in experimental medicine and biology,
J C Hiserodt, and L J Britvan, and S R Targan
August 1983, Cellular immunology,
J C Hiserodt, and L J Britvan, and S R Targan
January 1993, Microbiology and immunology,
J C Hiserodt, and L J Britvan, and S R Targan
July 1983, Immunobiology,
J C Hiserodt, and L J Britvan, and S R Targan
May 1980, Journal of immunology (Baltimore, Md. : 1950),
J C Hiserodt, and L J Britvan, and S R Targan
November 2004, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!